Evidence map›Paper›PMID 41874831›Full record

ArticlePurinergic signalling2026

Proteasomal-dependent endothelial P2Y

Nathalia F Oliveira, Matheus M L V Monteiro, Leticia D Crepaldi, Robson Coutinho-Silva, Luiz Eduardo B Savio, Claudia L Martins Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nathalia F OliveiraInstitute of Biomedical Sciences, ICB, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil.
Matheus M L V MonteiroInstitute of Biomedical Sciences, ICB, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil.
Leticia D CrepaldiInstitute of Biophysics Carlos Chagas Filho, IBCCF, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil.
Robson Coutinho-SilvaInstitute of Biophysics Carlos Chagas Filho, IBCCF, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil.
Luiz Eduardo B SavioInstitute of Biophysics Carlos Chagas Filho, IBCCF, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil.
Claudia L Martins SilvaInstitute of Biomedical Sciences, ICB, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil. cmartins@icb.ufrj.br.ORCID 0000-0001-9227-6036

Funding

Brazilian Federal Agency for Support and Evaluation of Graduate Education PIPD CAPESConselho Nacional de Desenvolvimento Científico e Tecnológico CNPq-Instituto Nacional Sinalização Purinérgica: Desafios para a saude do século 21 (No 409156/2024-8)Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro CNE, E-26/204.320/2024
6 · The paper itself

Abstract

Schistosomiasis, a complex chronic intravascular parasitic disease caused by Schistosoma mansoni, triggers a multifaceted host immune response and drives endothelial cells toward a sustained proinflammatory phenotype. The dysfunctional endothelial cells are a hallmark event that contributes to intestinal and liver damage mainly due to an increased monocyte adhesion, but the elevated morbidity unveils the lack of knowledge about disease pathogenesis. Purinergic P2Y

Indexed as

Cell AdhesionEndothelial CellsMonocytesProteasome Endopeptidase ComplexReceptors, Purinergic P2Schistosomiasis mansoniAnimalsDown-RegulationMaleMiceMice, Inbred C57BLProteasome Endopeptidase Complexpurinoceptor P2Y6Receptors, Purinergic P2Endothelial cellIntestinal inflammationP2Y6 receptorProteasomePurinergic signaling

Identifiers

PMID41874831
PMCPMC13013911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.